en · de · es · fr · pt
sr9009-notes.peptides3626.com › Topic › Background And Receptor Pharmacology — Deep Dive

Background And Receptor Pharmacology — Deep Dive

By Editorial Desk · published 2025-09-19 · last reviewed 2025-10-31 · Topic

If you have been reading about REV-ERB and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-10-31. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ in preclinical models
Molecular formulaC20H24ClN3O4SReported for the parent compound
CAS Registry Number1379686-30-2Common identifier in chemical databases
AppearanceOff-white to pale yellow solidTypical research chemical solid
SolubilitySoluble in DMSO and ethanol; low in waterClass: small organic molecule

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Related pages on this site

SR9009 Identity and Mechanism

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Background from the literature

== Self-assembling peptides versus carbon nanotubes == Carbon nanotubes (CNTs) are another type of nanomaterial that have attracted much interest for their potential to serve as building blocks for bottom-up applications. They have excellent mechanical, electrical, and thermal properties and can be fabricated to a wide range of nanoscale diameters, making them attractive and appropriate for the development of electronic and mechanical devices. They demonstrate metal-like properties and can act as remarkable conductors. However, there are several areas where peptides have advantages over CNTs. One advantage is that peptides have almost limitless chemical functionality compared with the very limited chemical interactions that CNTs can perform due to their non-reactiveness. Furthermore, CNTs exhibits strong hydrophobicity which results in a tendency to clump in aqueous solutions and therefore have limited solubility; their electrical properties are also affected by humidity, and the presence of oxygen, N2O, and NH3. It is also difficult to produce CNTs with uniform properties and this poses serious drawbacks as the reproducibility of precise structural properties is a key concern for commercial purposes. Lastly, CNTs are expensive, with prices in the range of hundreds of dollars per gram, rendering most applications commercially unviable.

== Contraindications == It should not be given, except if based on clinical need and under strict medical supervision, to people younger than 18 years old, as it can increase the risk of suicide attempts and suicidal thinking, and it can increase aggressiveness. While there is no evidence that it can harm a fetus from animal models, there are no data showing it safe for pregnant women to take. People with severe liver disease should not take mianserin, and it should be used with caution for people with epilepsy or who are at risk for seizures, as it can lower the threshold for seizures. If based on clinical decision, normal precautions should be exercised and the dosages of mianserin and any concurrent therapy kept under review and adjusted as needed.

Reform UK's deputy leader, Richard Tice, says a Reform government would scrap the Northern Powerhouse Rail project. Alliance Party MLA Nuala McAllister is ejected from the chamber of the Northern Ireland Assembly following a clash with deputy speaker Steve Aiken during which she described him as "patronising". 10 September – Prime Minister Keir Starmer meets Israeli President Isaac Herzog at 10 Downing Street for talks. Alison McGovern drops out of the Labour Party deputy leadership contest and gives her support to Bridget Phillipson. An investigation by the Senedd's Standards Commissioner concludes that Reform UK's Laura Anne Jones broke the rules by using a racial slur to describe Chinese people, but clears her of making fraudulent expenses claims. 11 September – Peter Mandelson is sacked from the post of UK Ambassador to the United States following revelations about his relationship with Jeffrey Epstein. The constituency office of Labour MP for Washington and Gateshead South Sharon Hodgson is destroyed in an arson attack. A man was arrested. Lucy Powell and Bridget Phillipson both receive enough nominations to contest the Labour Party deputy leadership election, while Bell Riberio-Addy pulls out of the contest after failing to secure enough support. Earlier in the day, Emily Thornberry and Paula Barker withdrew from the race. Sean Morgan, the leader of Caerphilly County Borough Council, resigns from Welsh Labour and joins Plaid Cymru, meaning he also relinquishes his post as council leader.

The Singaporean military, one of the smallest but most technologically advanced in Southeast Asia, consists of the Army, the Navy, the Air Force and the Digital and Intelligence Service. It is seen as the guarantor of the country's independence, translating into Singapore culture, involving all citizens in the country's defence. The government spent 2.7% of the country's GDP on the military in 2024, the highest in the region. After its independence, Singapore had only two infantry regiments commanded by British officers. Considered too small to provide effective security for the new country, the development of its military forces became a priority. In addition, in October 1971, Britain pulled its military out of Singapore, leaving behind only a small British, Australian and New Zealand force as a token military presence. A great deal of initial support came from Israel, a country unrecognised by Singapore's neighbouring Muslim-majority nations of Malaysia and Indonesia. The Israel Defense Forces (IDF) commanders were tasked by the Singapore Government to create the Singapore Armed Forces (SAF) from scratch, and Israeli instructors were brought in to train Singaporean soldiers. Military courses were conducted according to the IDF's format, and Singapore adopted a system of conscription and reserve service based on the Israeli model. Singapore still maintains strong security ties with Israel and is one of the biggest buyers of Israeli arms and weapons systems, with one recent example being the MATADOR anti-tank weapon.

Sources: en.wikipedia.org

Reference notes

More recent advances in synthetic platelet technology have focused on biomimetic approaches to replicate the essential functions of native platelets known as adhesion, aggregation, and clot formation. Platelet-mimetic nanoparticles are designed to imitate platelet behavior without the systemic risks associated with transfusion. These constructs can self-assemble into structures that bind to tumor endothelial cells and transform into nanofibers, initiating artificial coagulation at targeted sites. This ability to localize coagulation without systemic effects is being further researched for applications in treating both bleeding disorders and cancer, where controlled clotting is necessary to achieve positive patient outcomes. Emerging solutions for blood transfusions also aim to address current limitations of donor platelet products. Recent research has focused on creating synthetic platelet analogs that enable engineered constructs to selectively bind to thrombus sites, potentially enhancing the precision of clotting therapies for conditions such as thrombosis. Furthermore, integrating these platelet-mimetic features into drug delivery vehicles offers the potential for targeted therapies in cardiovascular disease, anti-inflammation treatments, and immunotherapies. Addressing safety, enhancing production methods, and managing regulatory approvals are challenges that need to be resolved before synthetic platelets can enter human clinical trial development and be routinely used in practice.

=== Taiwan === In October 2006, Taiwan banned ractopamine along with other beta-adrenergic agonists. In a 2012 climb-down, its legislature passed amendments to its Act Governing Food Sanitation, authorising government agencies to set safety standards for ractopamine. The Taiwanese Department of Health ultimately established an MRL of 10 ppb for ractopamine in beef on 31 July 2012. The American Institute in Taiwan, which represents US interests in Taiwan, states that these "and many other countries have determined that meat from animals fed ractopamine is safe for human consumption"; this is in the context of an ongoing trade dispute between Taiwan and the US on this subject, which threatened to prevent Taiwan's entry to the Trans-Pacific Partnership trade pact. In 2020, restrictions on imports of US pork with ractopamine were relaxed, leading to protests. A referendum took place on December 18, 2021, deciding whether to ban the import of pork with ractopamine, and the ban was rejected.

=== Extracellular signalling and neurotransmission === Cells secrete ATP to communicate with other cells in a process called purinergic signalling. ATP serves as a neurotransmitter in many parts of the nervous system, modulates ciliary beating, affects vascular oxygen supply etc. ATP is either secreted directly across the cell membrane through channel proteins or is pumped into vesicles which then fuse with the membrane. Cells detect ATP using the purinergic receptor proteins P2X and P2Y. ATP has been shown to be a critically important signalling molecule for microglia - neuron interactions in the adult brain, as well as during brain development. Furthermore, tissue-injury induced ATP-signalling is a major factor in rapid microglial phenotype changes.

Pascal's law (also Pascal's principle or the principle of transmission of fluid-pressure) is a principle in fluid mechanics that states that a pressure change at any point in a confined incompressible fluid is transmitted throughout the fluid such that the same change occurs everywhere. The law was established by French mathematician Blaise Pascal in 1653 and published in 1663.

Plant biologists use morphological characters of plants which can be compared, measured, counted and described to assess the differences or similarities in plant taxa and use these characters for plant identification, classification and descriptions. When characters are used in descriptions or for identification they are called diagnostic or key characters which can be either qualitative and quantitative.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Is SR9009 a hormone?

No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.

What is known about human use?

Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Network